The role of triple therapy in the management of COPD

References

• Sehl J, O’Doherty J, O’Connor R, et al. Adherence to COPD management guidelines in general practice? A review of the literature. Ir J Med Sci. 2018;187(2):403–407.
   PubMed Web of Science ®Google Scholar
• Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462.
   PubMed Web of Science ®Google Scholar
• Kilinc O, Konya A, Akgun M, et al. A case scenario study for the assessment of physician’s behavior in the management of COPD: the WHY study. Int J Chron Obstruct Pulmon Dis. 2018;13:2751–2758.
   PubMed Web of Science ®Google Scholar
• Kim TO, Shin HJ, Kim YI, et al. Adherence to the GOLD guideline in COPD management of South Korea: findings from KOCOSS study 2011-2018. Chonnam Med J. 2019;55(1):47–53.
   PubMedGoogle Scholar
• Pinto CR, Lemos ACM, Assunção-Costa L, et al. Management of COPD within the Brazilian unified health care system in the state of Bahia: an analysis of real-life medication use patterns. J Bras Pneumol. 2019;45(1):e20170194.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Triple combinations in chronic obstructive pulmonary disease - is three better than two? Expert Opin Pharmacother. 2014;15(17):2475–2478.
   PubMed Web of Science ®Google Scholar
• Maniscalco M, Martucci M, Fuschillo S, et al. A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of Southern Italy: the “Progetto PADRE”. Respir Med. 2020. DOI:https://doi.org/10.1016/j.rmed.2020.105985.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12–17.
   PubMed Web of Science ®Google Scholar
• Di Marco F, Santus P, Terraneo S, et al. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. NPJ Prim Care Respir Med. 2017;27(1):51.
   PubMed Web of Science ®Google Scholar
• Lane DC, Stemkowski S, Stanford RH, et al. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165‐1172.
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia. 2003;46(Suppl 1):M44–M50.
   PubMedGoogle Scholar
• Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31(5):251–258.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28(6):608–614.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Facciolo F, et al. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020;177(5):1150–1163.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Noschese P, Salzillo A, et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. 2005;99(5):524–528.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. The effective treatment of COPD: anticholinergics and what else? Drug Discov Today Ther Strateg. 2006;3(3):277–286.
   Google Scholar
• Falkingbridge S. Savopoulos J. COPD: the future is triple therapy. J Med Marketing. 2005;5(3):204–220.
   Google Scholar
• Rogliani P, Calzetta L, Cazzola M, et al. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opin Drug Saf. 2016;15(8):1133–1146.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Puxeddu E, et al. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: a pilot study. Pulm Pharmacol Ther. 2018;49:20–26.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Hanania NA. The role of combination therapy with corticosteroids and long-acting β2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):345–354.
   PubMedGoogle Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007;20(5):556–561.
   PubMed Web of Science ®Google Scholar
• Singh D, Brooks J, Hagan G, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63(7):592–598.
   PubMed Web of Science ®Google Scholar
• Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(8):741–750.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91–101.
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382–389.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–1162.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology. 2011;16(1):95–101.
   PubMed Web of Science ®Google Scholar
• Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med. 2010;104(3):412–417.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Shah M, D’Souza AO, et al. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res. 2012;13:15.
   PubMed Web of Science ®Google Scholar
• Short PM, Williamson PA, Elder DHJ, et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012;141(1):81–86.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest. 2004;126(1):220–237.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93–115.
   PubMedGoogle Scholar
• Calzetta L, Matera MG, Facciolo F, et al. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018;19(1):65.
   PubMed Web of Science ®Google Scholar
• Koziol-White C, Johnstone TB, Corpuz ML, et al. Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2020;318(2):L345–L355.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Rogliani P, et al. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018;12(4):261–264.
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252.
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Yost BL, Kumaravel B, et al. Glucocorticoid treatment increases inhibitory m2 muscarinic receptor expression and function in the airways. Am J Respir Cell Mol Biol. 2001;24(4):485–491.
   PubMed Web of Science ®Google Scholar
• Emala CW, Clancy J, Hirshman CA. Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle. Am J Physiol. 1997;272(4 Pt 1):L745–L751.
   PubMedGoogle Scholar
• Johnson M. Corticosteroids: potential β2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):320–341.
   PubMedGoogle Scholar
• Nabishah BM, Morat PB, Khalid BA, et al. Effect of acetylcholine and morphine on bronchial smooth muscle contraction and its modulation by steroid hormones. Clin Exp Pharmacol Physiol. 1990;17(12):841–847.
   PubMed Web of Science ®Google Scholar
• Muma NA, Beck SG. Corticosteroids alter G protein inwardly rectifying potassium channels protein levels in hippocampal subfields. Brain Res. 1999;839(2):331–335.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Fixed-dose combination inhalers. Handb Exp Pharmacol. 2017;237:117–129.
   PubMedGoogle Scholar
• Marceau C, Lemière C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118(3):574–581.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG,, . Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Ross CL, Hansel TT. New drug therapies for COPD. Clin Chest Med. 2014;35(1):219–239.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
   Google Scholar
• Langham S, Lewis J, Pooley N, et al. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respir Res. 2019;20(1):242.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8(F1000Faculty Rev):1533.
   Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626.
   PubMed Web of Science ®Google Scholar
• Kruis AL, Ställberg B, Jones RC, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355.
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250–258.
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Puxeddu E, et al. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018;12(1):43–54.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758–770.
   PubMed Web of Science ®Google Scholar
• Lee HW, Park J, Jo J, et al. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. PLoS Med. 2019;16(11):e1002958.
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Darken P, Ballal S, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple combinations in COPD: a systematic literature review and network meta-analysis. Adv Ther. 2020. DOI:https://doi.org/10.1007/s12325-020-01311-3.
   Google Scholar
• Lai CC, Chen CH, Lin CYH, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539–1548.
   PubMed Web of Science ®Google Scholar
• Faltinsen EG, Storebø OJ, Jakobsen JC, et al. Network meta-analysis: the highest level of medical evidence? BMJ Evid Based Med. 2018;23(2):56–59.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β-agonists in COPD: accumulating evidence from network meta-analyses. Pulm Ther. 2019;5(2):117–126.
   PubMedGoogle Scholar
• López-Campos JL, Carrasco-Hernández L, Román Rodríguez L, et al. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol. 2020;56(4):242‐248.
   Web of Science ®Google Scholar
• Bremner PR, Birk R, Brealey N, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19.
   PubMedGoogle Scholar
• Hoevelmann R, Georges G, Bahari Javan S, et al. Trioptimize VI: the use of extrafine single inhaler triple therapy improves adherence to treatment in patients with COPD - real-world evidence [abstract]. Am J Respir Crit Care Med. 2020;201:A4303.
   Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Matera MG, et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019;20(6):737–750.
   PubMed Web of Science ®Google Scholar
• Day NC, Kumar S, Criner G, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020;21(1):139.
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219.
   PubMed Web of Science ®Google Scholar
• Global GOLD Strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD). 2020 Report. [cited Apr 29 2020]. Available from: https://goldcoped.org/
   Google Scholar
• Stolz D, Miravitlles M. The right treatment for the right patient with COPD: lessons from the IMPACT trial. Eur Respir J. 2020;55(5):2000881.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Ullman A, Nordenson A, et al. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019;5(1):00185–2018.
   PubMedGoogle Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Matera MG. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015;75(14):1575–1585.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European respiratory society guideline. Eur Respir J. 2020;55(6):2000351.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Carrasco-Hernandez L, Quintana-Gallego E, et al. Triple therapy for COPD: a crude analysis from a systematic review of the evidence. Ther Adv Respir Dis. 2019;13:1753466619885522.
   Web of Science ®Google Scholar
• Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.
   PubMed Web of Science ®Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101841.
   PubMed Web of Science ®Google Scholar